Vantage Investment Partners LLC Boosts Position in Eli Lilly and Company (NYSE:LLY)

Vantage Investment Partners LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 175.1% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 47,643 shares of the company's stock after buying an additional 30,322 shares during the quarter. Eli Lilly and Company makes up about 3.3% of Vantage Investment Partners LLC's investment portfolio, making the stock its 8th largest holding. Vantage Investment Partners LLC's holdings in Eli Lilly and Company were worth $39,349,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in LLY. Guyasuta Investment Advisors Inc. raised its stake in shares of Eli Lilly and Company by 2.2% during the first quarter. Guyasuta Investment Advisors Inc. now owns 2,985 shares of the company's stock valued at $2,465,000 after purchasing an additional 64 shares in the last quarter. North Point Portfolio Managers Corp OH grew its holdings in Eli Lilly and Company by 151.5% during the first quarter. North Point Portfolio Managers Corp OH now owns 1,826 shares of the company's stock worth $1,508,000 after acquiring an additional 1,100 shares during the period. Childress Capital Advisors LLC grew its holdings in Eli Lilly and Company by 3.3% during the first quarter. Childress Capital Advisors LLC now owns 2,493 shares of the company's stock worth $2,059,000 after acquiring an additional 79 shares during the period. Moisand Fitzgerald Tamayo LLC grew its holdings in Eli Lilly and Company by 11.3% during the first quarter. Moisand Fitzgerald Tamayo LLC now owns 216 shares of the company's stock worth $178,000 after acquiring an additional 22 shares during the period. Finally, MinichMacGregor Wealth Management LLC grew its holdings in Eli Lilly and Company by 1,164.9% during the first quarter. MinichMacGregor Wealth Management LLC now owns 11,574 shares of the company's stock worth $9,559,000 after acquiring an additional 10,659 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 2.8%

Shares of NYSE LLY opened at $763.43 on Monday. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market capitalization of $723.53 billion, a PE ratio of 62.12, a PEG ratio of 1.11 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $780.48 and a two-hundred day moving average price of $800.76.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the business posted $2.58 earnings per share. The company's revenue was up 45.2% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company's payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of research firms recently issued reports on LLY. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, June 7th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.79.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.